Harvard College

Other

James Hogle

Diane Marie Joseph-McCarthy

Harmon J Zuccola

Carl Elkin

George M Whitesides

Kristie Grove Bridges

Donald M Coen

Martin Karplus

Scott Lokey

David Filman

Simon K Tsang

Lyle D Isaacs

James Li-wen Cheh

A method for the structure-based identification and selection of inhibitors of processivity factor binding to protein is disclosed herein. Characterization of the protein/processivity factor interface is given. Methods for the structure-based inhibition of processivity factor binding to protein are also given. One embodiment includes a class of peptidomimetics that mimic helical portions of proteins. In addition, methods of treatment of various diseases are given, using the inhibitors of the invention.

Structure-based approach to design of inhibitors of protein-processivity factor interactions

This invention relates to HDAg peptides, including mutants, derivatives fragments and fusion molecules, including fusion proteins, coiled-coil oligomers, nucleic acid molecules, vectors comprising HDAg nucleic acid molecules, cells comprising said molecules, methods of multivalent expression and association of binding moieties of HDAg fusion molecules, and methods of use involving the molecules. The molecules are particularly useful as a framework for multivalent display via formation of C-terminal and/or N-terminal fusion proteins or via chemical coupling to chemically reactive sidechains, e.g. cysteine residues.

Oligomerization of hepatitis delta antigen

The present invention is broadly directed to methods of screening viral-binding compounds. In particular, the present invention provides cell-free assays to rapidly screen libraries of compounds for viral-capsid binding activity. Such compounds are useful for anti-viral treatments.

Method for identifying new anti-picornaviral compounds

The present invention provides structure-based combinatorial libraries of compounds containing the functional group minima of picornaviruses including poliovirus and rhinovirus. The libraries can be used to screen for therapeutical antiviral compounds, e.g., anti-picornaviral capsid-binding compounds.

Anti-picornaviral ligands via a combinatorial computational and synthetic approach

Growing community of inventors

Newton, MA, United States of America

James Hogle